Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib-Reference-Cited by-同舟云学术

Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib

Published:2019-05 Issue:5 Volume:14 Page:e95-e96
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Mehlman Camille,Chaabane Nouha,Lacave Roger,Kerrou Khaldoun,Ruppert Anne Marie,Cadranel Jacques,Fallet Vincent

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non–small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study;Duruisseaux;Oncotarget,2017

2. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non–small cell lung cancer;Noh;J Pathol,2017

3. Emergence of new ALK mutations at relapse of neuroblastoma;Schleiermacher;J Clin Oncol,2014

4. Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status;Bazhenova;J Clin Oncol,2017

5. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK Inhibitors in preclinical models;Zhang;Clin Cancer Res,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10

2. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

3. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma;Nature Communications;2024-04-23

4. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC);Diagnostics;2023-12-25

5. Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure;Expert Review of Anticancer Therapy;2023-10-05